International experts identified eight research priorities covering biomarker-guided chemoradiation, immunotherapy sequencing, and consolidation radiotherapy in metastatic head and neck cancer.
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Twelve trials used 14 immunotherapy regimens with major differences in eligibility, radiotherapy, chemotherapy, endpoints, and translational analysis.
Radiation reached 60 Gy in 15 fractions with adjuvant atezolizumab, while concurrent dosing was followed by HSV-1 reactivation in three of five patients.
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
Consolidation durvalumab after concurrent chemoradiotherapy halved the adjusted risk of progression or death at two years in real-world stage III NSCLC.
This systematic review found that optimal radiotherapy-immunotherapy sequencing depends on the immune mechanism being targeted.
TREASURE found no survival benefit and higher serious toxicity with thoracic radiotherapy added to atezolizumab maintenance.
Immuno-Eclipse radiotherapy improved bulky tumor control in mice through natural killer and cytotoxic T-cell immunity.
Adding early stereotactic body radiotherapy to neoadjuvant chemoimmunotherapy was associated with median progression-free survival of 12.5 versus 6.6 months.
Radiotherapy increased tumor uptake of PDL1-targeted radionuclide therapy, while antibody co-dosing reduced splenic trapping and restored antitumor efficacy in mice.